GLP-1 Drugs Cause Frequent Gut Side Effects but Largely Preserve Lean Mass, Review Finds
A review of 16 randomized trials (7,096 adults) finds GLP-1 and tirzepatide therapy raises GI symptoms despite diet support, while lean mass looks largely preserved.
Summary
GLP-1 and dual GIP/GLP-1 drugs like semaglutide, liraglutide and tirzepatide are usually paired with diet and exercise advice, but little is known about the best nutrition approach alongside them. This systematic review pooled 16 randomized trials with 7,096 adults. Nausea, diarrhea, constipation and vomiting were consistently more common on the drugs than on placebo, often rising with dose, and diet and exercise support did not prevent them. Where body composition was measured, lean mass was largely preserved, with losses in line with overall weight loss. No trial studied bone health, and none reported clinically relevant nutrient deficiencies. The authors conclude that evidence on protein needs and optimal dietary strategies is still thin, and that more targeted trials are needed.
Detailed Summary
GLP-1 receptor agonists and the dual GIP/GLP-1 agonist tirzepatide have become mainstays for obesity, prediabetes and type 2 diabetes, and guidelines say they should always be paired with diet and exercise. Because these drugs blunt appetite and cut energy intake, clinicians worry about lost muscle, weaker bone and micronutrient shortfalls. All of these matter for healthspan, since sarcopenia and frailty drive functional decline with age. Yet nutrition advice given alongside these drugs remains largely empirical, with no consensus on what works best.
This systematic review, registered in PROSPERO (CRD420251181076) and reported under PRISMA, searched PubMed, Embase, Scopus and Web of Science in October 2025. From 6,351 citations (4,780 after de-duplication) and 63 full-text articles, 16 randomized trials with 7,096 adults aged 18 to 75 were included. Sample sizes ranged from 40 to 3,723 and durations from 12 to 88 weeks. Drugs included liraglutide, semaglutide, dulaglutide, efpeglenatide, albiglutide and tirzepatide, mostly compared with placebo. Background lifestyle support typically meant a 500 kcal/day deficit, counseling and at least 150 minutes weekly of physical activity.
Gastrointestinal symptoms were the most consistent finding. Liraglutide trials showed nausea in 63% versus 19% with placebo (Halawi) and 67% versus 26% (Kim), and overall GI events in 88.5% versus 34.6% (Nexøe-Larsen). Semaglutide 2.4 mg produced diarrhea in 28.2% versus 6.7% and nausea in 20.5% versus 4.8% (Gu), with a dose gradient in Lingvay: 53.1% at 7.2 mg, 51.5% at 2.4 mg and 25.5% on placebo. Early tirzepatide exposure brought nausea in 35.5%, diarrhea in 21.1%, constipation in 20.7% and vomiting in 16.3%, though events declined during the double-blind period. Albiglutide showed only a mild excess.
Lifestyle support did not blunt these effects. In Sandsdal's trial, GI events occurred in 71% to 86% of liraglutide groups, including those exercising, versus 45% on placebo. No trial compared nutritional guidance with no guidance, so the review cannot say whether diet counseling reduces symptoms. Despite the symptoms, dietary adherence was similar between drug and placebo arms in Neil et al., and the large Pi-Sunyer trial (n=3,723) maintained the prescribed caloric deficit.
Muscle data were sparse, with only three trials measuring body composition. Kadouh found lean mass fell 1.3 kg with liraglutide versus 0.65 kg with placebo over 16 weeks, which the authors attributed to greater overall weight loss. Zhang (dulaglutide versus caloric restriction) and Lundkvist (dapagliflozin plus exenatide) found no significant lean-mass differences. No trial assessed bone health, and none reported clinically relevant nutritional deficiencies, although nutritional status was not a formal endpoint. By JBI criteria, 13 of 16 studies (81.25%) had low risk of bias, two had high risk and one was unclear.
The caveats are substantial. The trials were designed to test drug safety and efficacy, not nutrition, so protein intake, micronutrient status and diet quality were rarely measured. The lean-mass conclusion rests on three small studies, and the larger absolute loss with liraglutide in one trial argues for caution. Protein targets, resistance training and bone outcomes remain open questions, and the authors call for dedicated trials to establish evidence-based dietary recommendations.
Key Findings
- 16 randomized trials with 7,096 adults (sample sizes 40 to 3,723; durations 12 to 88 weeks) were included from 6,351 initial citations
- Liraglutide increased nausea to 63% vs 19% on placebo (Halawi) and 67% vs 26% (Kim); overall GI events were 88.5% vs 34.6% (Nexøe-Larsen)
- Semaglutide showed a dose-related GI burden: 53.1% at 7.2 mg, 51.5% at 2.4 mg and 25.5% on placebo (Lingvay)
- Tirzepatide's initial phase brought nausea in 35.5%, diarrhea in 21.1%, constipation in 20.7% and vomiting in 16.3%, declining during the double-blind period
- Exercise did not prevent GI events: 71% to 86% in liraglutide groups vs 45% on placebo (Sandsdal)
- Only 3 trials measured body composition; lean mass loss was 1.3 kg with liraglutide vs 0.65 kg with placebo (Kadouh), with no significant differences in two other trials
- No trial assessed bone health, none reported clinically relevant nutritional deficiencies, and 13 of 16 trials (81.25%) had low risk of bias
Methodology
This PRISMA-guided systematic review was prospectively registered in PROSPERO (CRD420251181076) and searched PubMed/MEDLINE, Embase, Scopus and Web of Science in October 2025 with no language or date limits. Two reviewers independently screened records in Rayyan, with a third resolving disagreements, and two reviewers independently extracted data. Eligible studies were randomized trials in adults with overweight, obesity, prediabetes or type 2 diabetes treated with GLP-1 or dual GIP/GLP-1 agonists alongside lifestyle or dietary guidance. Risk of bias was rated with the 13-item JBI randomized trial checklist, and results were synthesized narratively with no meta-analysis. Two otherwise eligible studies could not be accessed and were excluded.
Study Limitations
Most trials were designed to assess drug safety and efficacy, so nutritional intake, protein, micronutrient status and bone outcomes were rarely measured, and no trial compared nutritional intervention with none. Body composition was assessed in only three trials, and the lean-mass conclusion rests on small samples. Heterogeneity in populations, drugs, doses, diets and durations precluded meta-analysis, and two eligible studies could not be accessed. No conflict-of-interest statement was included in the supplied text.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: